文献速递细菌感染、耐药与抗菌药物

我如何管理MRSA菌血症患者

How I manage a patient with MRSA bacteraemia.
PubMed 文献 · Clin Microbiol Infect · 2021-10-29

本文以MRSA菌血症合并原发性骨关节感染为例,讨论经验性抗生素选择、MRSA目标治疗、万古霉素监测与剂量、持续性菌血症的联合治疗、疗程及口服转换等关键决策点。推荐优先基于随机临床试验数据,缺乏时依据作者经验与意见;强调积极源头控制与个体化而非流程化管理,并指出需进一步随机对照试验。

要点

  • 疑似金黄色葡萄球菌菌血症的经验性抗生素选择需结合MRSA风险。
  • 万古霉素监测与剂量调整是MRSA菌血症管理的关键环节。
  • 持续性菌血症可考虑联合治疗,疗程及口服转换需个体化决策。

核心结论

  • 金黄色葡萄球菌菌血症常见且死亡率高(15-25%),MRSA菌血症占10-40%且死亡率更高。
  • 尽管是临床感染病实践的「 bread and butter 」,但指导最佳管理的稳健证据常缺乏,实践差异大。
  • 广泛原则(积极源头控制和适当抗生素选择与疗程)重要,但金黄色葡萄球菌菌血症的异质性意味着常需个体化而非流程化管理。
  • 需要进一步随机对照试验以加强MRSA菌血症管理的证据基础。

研究设计与样本

  • 基于近期相关主题文献检索的讨论,以MRSA菌血症合并原发性骨关节感染的真实病例为例,展示作者在关键管理决策点的思考过程。
  • 制定推荐时优先并突出随机临床试验数据,缺乏时推荐基于作者的经验和意见。

主要发现

  • 讨论了疑似金黄色葡萄球菌菌血症的经验性抗生素选择。
  • 讨论了MRSA的目标抗生素选择。
  • 讨论了万古霉素的监测与剂量。
  • 讨论了菌血症持续时的联合治疗作用。
  • 讨论了疗程及转换为口服抗生素的作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 指导最佳管理的稳健证据常缺乏。
  • 实践差异大。
  • 需要进一步随机对照试验以加强MRSA菌血症管理的证据基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Staphylococcus aureus bloodstream infections are common and associated with a high mortality of 15-25%. Methicillin-resistant S. aureus (MRSA) bloodstream infection accounts for 10-40% of cases, and has an even higher mortality. Despite being the 'bread and butter' of clinical infectious diseases practice, robust evidence to guide optimal management is often lacking and there is wide variation in practice. OBJECTIVES: To provide a real-world example of a case of MRSA bacteraemia and the thought processes of the authors as key management decision points are reached. SOURCES: The discussion is based on recent literature searches of relevant topics. In making recommendations, randomized clinical trial data have been prioritized and highlighted, and where these are not available recommendations are based on the experience and opinions of the authors. CONTENT: For a patient with MRSA bacteraemia and a primary bone and joint infection the following points are discussed: empirical antibiotic choice for suspected S. aureus bacteraemia; directed antibiotic choice for MRSA; monitoring and dosing of vancomycin; the role of combination therapy when bacteraemia is persistent; and the duration of therapy and role of switching to oral antibiotics. IMPLICATIONS: While broad principles of aggressive source control and appropriate choice and duration of antibiotics are important, the heterogeneity of S. aureus bacteraemia means that a tailored rather than algorithmic approach to management is often required. Further randomized controlled trials are needed to strengthen the evidence base for the management of MRSA bacteraemia.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Davis JS, Petersiel N, Tong SYC, et al. How I manage a patient with MRSA bacteraemia. Clin Microbiol Infect. 2021. PMID: 34757117. doi:10.1016/j.cmi.2021.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。